Terminal myelocystocele

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:645337Q05.9
Who is this for?
Show terms as
View depth
15Specialists8Treatment centers

Where are you in your journey?

UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data

What is Terminal myelocystocele?

Terminal myelocystocele does not yet have FDA-approved treatments tracked on UniteRare.

Inheritance
Sporadic
Usually appears on its own, not inherited from a parent
Age of Onset
Neonatal
Begins at or shortly after birth (first 4 weeks)
Orphanet ↗NORD ↗

Treatments

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

No FDA-approved treatments are currently listed for Terminal myelocystocele.

View clinical trials →

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

No actively recruiting trials found for Terminal myelocystocele at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Terminal myelocystocele community →

Specialists

15 foundView all specialists →

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

NM
Nobutaka Mukae
Specialist
3 Terminal myelocystocele publications
TS
Takafumi Shimogawa
Specialist
3 Terminal myelocystocele publications
SS
Satoshi O Suzuki
Specialist
3 Terminal myelocystocele publications
TM
Takato Morioka
Specialist
3 Terminal myelocystocele publications
KY
Koji Yoshimoto
Specialist
2 Terminal myelocystocele publications
AK
Ai Kurogi
Specialist
3 Terminal myelocystocele publications
NM
Nobuya Murakami
Specialist
3 Terminal myelocystocele publications
DM
Daniela Sol Massa
Specialist
1 Terminal myelocystocele publication
SM
Santiago Adalberto Portillo Medina
SAN JUAN, PR
Specialist
1 Terminal myelocystocele publication
NM
Nicolas Arturo Montivero
Specialist
1 Terminal myelocystocele publication
SK
S Berchi Kankam
Specialist
1 Terminal myelocystocele publication
MA
M Ashrafi
Specialist
1 Terminal myelocystocele publication
KM
K Tayebi Meybodi
Specialist
1 Terminal myelocystocele publication
ZH
Z Habibi
FORT WORTH, TX
Specialist
1 Terminal myelocystocele publication
MA
M Sotoudeh Anvari
ANNAPOLIS, MD
Specialist
1 Terminal myelocystocele publication

Treatment Centers

8 centers

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

🏨 Children's

Children's Hospital Colorado Rare Disease Program

Children's Hospital Colorado

📍 Aurora, CO

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Boston Children's Hospital Rare Disease Program

Boston Children's Hospital

📍 Boston, MA

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

🏨 Children's

Ann & Robert H. Lurie Children's Hospital Genetics

Lurie Children's Hospital

📍 Chicago, IL

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

Cincinnati Children's Hospital Medical Center

Cincinnati Children's

📍 Cincinnati, OH

👤 Boston Children's Hospital Rare Disease Program

🏨 Children's

Nationwide Children's Hospital Rare Disease Center

Nationwide Children's Hospital

📍 Columbus, OH

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to Terminal myelocystocele.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Terminal myelocystoceleForum →

No community posts yet. Be the first to share your experience with Terminal myelocystocele.

Start the conversation →

Latest news about Terminal myelocystocele

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

No recent news articles for Terminal myelocystocele.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Terminal myelocystocele

What is Terminal myelocystocele?

Terminal myelocystocele is a rare form of closed (skin-covered) spinal dysraphism, classified as a type of spina bifida. In this condition, the terminal portion of the spinal cord herniates through a posterior bony defect in the lower spine (typically the sacral region) and forms a cyst-like dilation of the central canal (hydromyelia) that expands into a meningocele sac. Unlike open neural tube defects, the lesion is covered by skin, which may appear as a large, skin-covered lumbosacral mass at birth. Terminal myelocystocele is sometimes referred to as syringocele or terminal syringocele and f

How is Terminal myelocystocele inherited?

Terminal myelocystocele follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Terminal myelocystocele typically begin?

Typical onset of Terminal myelocystocele is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Terminal myelocystocele?

15 specialists and care centers treating Terminal myelocystocele are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

Frequently asked questions about Terminal myelocystocele

Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.

  1. What is Terminal myelocystocele?

    Terminal myelocystocele is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:645337). It is typically inherited as sporadic. Age of onset is generally neonatal. For verified primary sources, see the UniteRare Terminal myelocystocele page.

  2. How is Terminal myelocystocele inherited?

    Terminal myelocystocele follows sporadic inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.

  3. Are there FDA-approved treatments for Terminal myelocystocele?

    Approved treatments for Terminal myelocystocele are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.

  4. Are there clinical trials for Terminal myelocystocele?

    Active clinical trials for Terminal myelocystocele are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.

  5. How do I find a specialist for Terminal myelocystocele?

    UniteRare lists 15 verified clinicians with documented expertise in Terminal myelocystocele, sourced from ClinicalTrials.gov principal-investigator records, PubMed publication histories, and the NPPES NPI registry. Filter by state or browse our state-specific specialist pages for nearby options.

See full Terminal myelocystocele page for complete clinical details, sources, and verified-specialist listings.

Cite this page

Select a citation format above to view and copy.